1031

● 0/20/60 ) OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/709,905A

DATE: 12/13/2001 TIME: 20:27:05

Input Set : N:\Crf3\Refhold\I709905A.raw
Output Set: N:\CRF3\12132001\I709905A.raw

```
ENTERED
     1 <110> APPLICANT: Kalyanaraman Ramnarayan
             Edward T. Maggio
             P. Patrick Hess
      4 <120> TITLE OF INVENTION: Use of Computationally Derived Protein
              Structures of Genetic Polymorphisms in Pharmacogenomics for
             Drug Design and Clinical Applications
     7 <130> FILE REFERENCE: 24737-1906C
                                                                          RECEIVED
C--> 8 <140> CURRENT APPLICATION NUMBER: US/09/709,905A
     9 <141> CURRENT FILING DATE: 2000-11-10
                                                                             FEB 0 6 2002
    10 <150> PRIOR APPLICATION NUMBER: 09/438,566
    11 <151> PRIOR FILING DATE: 1999-11-10
    12 <150> PRIOR APPLICATION NUMBER: 24737-1906B
                                                                        TECH CENTER 1600/2900
    13 <151> PRIOR FILING DATE: 2000-11-01
    14 <160> NUMBER OF SEQ ID NOS: 118
    15 <170> SOFTWARE: FastSEQ for Windows Version 4.0
    17 <210> SEQ ID NO: 1
    18 <211> LENGTH: 6
    19 <212> TYPE: PRT
    20 <213> ORGANISM: Artificial Sequence
    21 <220> FEATURE:
    22 <223> OTHER INFORMATION: Modified Hepatitis C Virus NS3 Protease Inhibitor
             Peptide
    24 <221> NAME/KEY: ACETYLATION
    25 <222> LOCATION: 1
    26 <221> NAME/KEY: MOD_RES
    27 <222> LOCATION: 2
    28 <223> OTHER INFORMATION: D-glutamic acid
    29 <221> NAME/KEY: MOD_RES
    30 <222> LOCATION: 5
    31 <223> OTHER INFORMATION: beta-cyclohexylalanine
    32 <300> PUBLICATION INFORMATION:
    33 <301> AUTHORs: Ingallinella, P., Altamura, S., Bianchi, E., Talia
    34 <302> TITLE: Potent Peptide Inhibitors Of Human Hepatitis C Vir
    35 <303> JOURNAL: Biochemistry
    36 <304> VOLUME: 37
    37 <305> ISSUE: 25
    38 <306> PAGES: 8906-8914
    39 <307> DATE: 1998-06-23
    40 <400> SEQUENCE: 1
             Asp Xaa Leu Ile Xaa Cys
    44 <210> SEQ ID NO: 2
    45 <211> LENGTH: 6
    46 <212> TYPE: PRT
    47 <213> ORGANISM: Artificial Sequence
    48 <220> FEATURE:
    49 <223> OTHER INFORMATION: Modified Hepatitis C Virus NS3 Protease Inhibitor
```



PATENT APPLICATION: US/09/709,905A

DATE: 12/13/2001 TIME: 20:27:05

Input Set : N:\Crf3\Refhold\I709905A.raw Output Set: N:\CRF3\12132001\1709905A.raw

```
51 <221> NAME/KEY: ACETYLATION
     52 <222> LOCATION: 1
     53 <221> NAME/KEY: MOD_RES
     54 <222> LOCATION: 5
     55 <223> OTHER INFORMATION: beta-cyclohexylalanine
     56 <300> PUBLICATION INFORMATION:
     57 <301> AUTHORs: Ingallinella, P., Altamura, S., Bianchi, E., Talia
     58 <302> TITLE: Potent Peptide Inhibitors Of Human Hepatitis C Vir
     59 <303> JOURNAL: Biochemistry
     60 <304> VOLUME: 37
     61 <305> ISSUE: 25
     62 <306> PAGES: 8906-8914
     63 <307> DATE: 1998-06-23
    64 <400> SEQUENCE: 2
              Asp Glu Leu Ile Xaa Cys
     66
     68 <210> SEQ ID NO: 3
     69 <211> LENGTH: 1045
    70 <212> TYPE: DNA
    71 <213> ORGANISM: Human Immunodeficiency Virus (HIV)
    72 <220> FEATURE:
    73 <221> NAME/KEY: CDS
    74 <222> LOCATION: (1)...(297)
    75 <223> OTHER INFORMATION: Protease
    76 <221> NAME/KEY: CDS
    77 <222> LOCATION: (298)...(1045)
    78 <223> OTHER INFORMATION: Portion of Reverse Transcriptase
    79 <400> SEQUENCE: 3
              cct cag atc act ctt tgg caa cga ccc cty gtc aca ata aag ata ggg
                                                                                      48
W--> 81
              Pro Gln Ile Thr Leu Trp Gln Arg Pro Xaa Val Thr Ile Lys Ile Gly
    82
                                                    10
    83
              ggc caa cta aaa gaa gct yta tta gat aca gga gca gat gat aca gta
                                                                                      96
              Gly Gln Leu Lys Glu Ala Xaa Leu Asp Thr Gly Ala Asp Asp Thr Val
    84
    85
                           20
             tta gaa gaa atg agt tta cca ggg aaa tgg aaa cca aaa atg ata ggg
    86
                                                                                     144
             Leu Glu Glu Met Ser Leu Pro Gly Lys Trp Lys Pro Lys Met Ile Gly
    87
    88
                       35
                                            40
    89
             gga att gga ggt ttt atc aaa gta aga cag tat gat caa ata ctc ata
                                                                                     192
    90
             Gly Ile Gly Gly Phe Ile Lys Val Arg Gln Tyr Asp Gln Ile Leu Ile
    91
    92
             gaa atc tgt gga cat aaa gct ata ggc aca gta tta gta gga cct aca
                                                                                     240
    93
             Glu Ile Cys Gly His Lys Ala Ile Gly Thr Val Leu Val Gly Pro Thr
    94
                                   70
                                                        75
    95
             cct gtc aac ata att gga aga aat ttg ttg act cag att ggt tgc act
                                                                                     288
    96
             Pro Val Asn Ile Ile Gly Arg Asn Leu Leu Thr Gln Ile Gly Cys Thr
    97
                               85
                                                    90
    98
             tta aat ttg ccc att agt cct att gaa act gta cca gta aaa tta aag
                                                                                     336
    99
             Leu Asn Leu Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys
```

50

Peptide



DATE: 12/13/2001 PATENT APPLICATION: US/09/709,905A TIME: 20:27:05

Input Set : N:\Crf3\Refhold\I709905A.raw Output Set: N:\CRF3\12132001\I709905A.raw

											_								
	100					100					105					110			
	101		cca	gga	atg	gat	ggc	cca	aaa	gtt	aaa	caa	tgg	cca	ttg	aca	gaa	gaa	384
	102		Pro	Gly	Met	Asp	Gly	Pro	Lys	Val	Lys	Gln	Trp	Pro	Leu	Thr	Ğlu	Ğlu	
	103				115					120					125				
	104		aaa	ata	aaa	gca	tta	gta	gaa	att	tgt	aca	gaa	atg	gaa	aag	gaa	gga	432
	105		Lys	Ile	Lys	Ala	Leu	Val	Glu	Ile	Cys	Thr	Glu	Met	Glu	Lys	Ğlu	Gly	
	106			130					135					140				_	
	107		aaa	att	tca	aaa	att	ggg	cct	gag	aat	cca	tac	aat	act	cca	ata	ttt	480
	108		Lys	Ile	Ser	Lys	Ile	Gly	Pro	Glu	Asn	Pro	Tyr	Asn	Thr	Pro	Ile	Phe	
	109		145					150					155					160	
	110		gcc	ata	aag	aaa	aaa	gac	agt	act	aaa	tgg	aga	aaa	tta	gta	gat	ttc	528
	111		Ala	Ile	Lys	Lys		Asp	Ser	Thr	Lys	Trp	Arg	Lys	Leu	Val	Asp	Phe	
	112						165					170					175		
	113		aga	gaa	ctt	aat	aag	aga	aca	caa	gac	ttc	tgg	gaa	gtt	caa	tta	gga	576
	114		Arg	Glu	Leu	Asn	Lys	Arg	Thr	Gln		Phe	Trp	Glu	Val	Gln	Leu	Gly	
	115					180					185					190			
	116		ata	cca	cac	ccc	gca	ggg	tta	aaa	cag	aaa	aaa	tca	gta	aca	ata	ctg	624
	117		тте	Pro		Pro	Ala	Gly	Leu		Gln	Lys	Lys	Ser	Val	Thr	Ile	Leu	
	118				195					200					205				
	119		gat	gtg	ggt	gat	gca	tat	ttt	tca	gtt	ccc	tta	gat	gaa	ggc	ttc	agg	672
	120		Asp		GLY	Asp	Ala	Tyr		Ser	Val	Pro	Leu		Glu	Gly	Phe	Arg	
	121 122			210					215					220					
			aag	tat	act	gca	ttt	acc	ata	cct	agt	aga	aat	aat	gag	aca	cca	ggg	720
	123 124		225	туг	Thr	Ата	Pne	Thr	тте	Pro	Ser	Arg		Asn	Glu	Thr	Pro	_	
	125			202	+-+			230					235					240	
	126		Tla	aya	Terr.	cag	Lac	aac	grg	CTC	cca	cag	gga	tgg	aaa	gga	tca	cca	768
	127		116	Arg	ıyı	GIII	245	Asn	vaı	Leu	Pro		GTĀ	Trp	Lys	GLY		Pro	
,	128		aca	2+2	+++			200	a+ ~			250					255		
′	129		y Ca	Tla	Dho	Cla	ayı Com	agc	acg	aca	aga	aty	tta	gag	cct	ttt	aga -	aaa	816
	130		ALG	116	тие	260	ser	Ser	MeL	THE	265	хаа	Leu	GLU	Pro		Arg	Lys	•
	131		caa	aat	cca		ata	gtt	a t o	+ = +		+20	2+~	~~+	~~+	270			264
	132		Gln	Asn	Pro	Glu	Tle	Val	Tla	Тиг	Cln	Tur	a Ly	yaı	yaı.	ttg	Tat	gta	864
	133				275	O L u	110	vuı	116	280	GIII	тАт	Met	ASP	285	ьeu	туг	vaı	
	134		σσα	tet		tta	αаа	ata	gga		cat	ara	aca.	222		~~~	<b>~</b> ~ ~ ~	a+~	010
	135		Glv	Ser	Asp	Leu	Glu	Ile	Glv	Gln	Hie	Ara	y Ca	Luc	Tla	Clu	Clu	CLG	912
	136		- 1	290					295	0		my	nia	300	116	Giu	GIU	ьеи	
	137		aga	qqa	cat	cta	tta	aag		gga	+++	acc	aca		nan	222	222	ant.	960
	138		Arq	Gly	His	Leu	Leu	Lys	Tro	Glv	Phe	Thr	Thr	Dro	Aen	T.ve	Luc	Dic	900
	139		305	•				310	<b>F</b>	1			315	110	p	Lys	пуз	320	
	140		cag	aaa	qaa	cct	cca	ttt	ct.t	t.aa	atσ	aat		αаа	ctc	cat	cat	72 t	1008
	141		Gln	Lys	Ğlu	Pro	Pro	Phe	Leu	Trp	Met	Glv	Tvr	Glu	Leu	Hig	Dro	Aan	1000
	142			_			325					330	-1-				335	пор	
	143		aaa	tgg	aca	gta	caq	cct	ata	aaq	tta		σaa	aaa	σ				1045
	144		Lys	Trp	Thr	val	Gln	Pro	Ile	Lys	Leu	Pro	Glu	Lys	J				1042
	145					340				-	345	-		-4-					
		<210>.																	
		<211>																	
	149	<212>	TYPE	: DN	Α														



DATE: 12/13/2001 PATENT APPLICATION: US/09/709,905A TIME: 20:27:05

Input Set : N:\Crf3\Refhold\I709905A.raw Output Set: N:\CRF3\12132001\1709905A.raw

	<213>				uman	Imm	unod	efic	ienc	y Vi	rus	(HIV	·)					
			FEATURE:															
			NAME/KEY: CDS															
			LOCATION: (1)(297) OTHER INFORMATION: HIV Protease															
			NAME/KEY: CDS															
	<222>								<b>-</b>									
15)	<223>	OTH	EK I	NFOR	MATT	ON:	Port	10n	of H	IV R	ever	se T	rans	crip	tase			
159	<400>																	
160		DTO	Cag	alc	act	CLL	tgg	caa	cga	ccc	ctt	gtc	aca	ata	aag	ata	gga	48
161		1	GIII	тте	THE		Trp	GIN	Arg	Pro		Val	Thr	Ile	Lys		Gly	
162		_	a 2 a	a+ a	226	5	~~+				10					15		
163		999 Cl.	Can	Tou	aay	yaa ci	310	Cta	tta	gat	aca	gga	gca	gat	gat	aca	gta	96
164		GIY	GIII	ьeu	ьуs 20	GIU	Ата	ьeu	Leu		Thr	GTĀ	Ата	Asp	_		Val	
165		α++	ma a	~~~		22+	++~	999	~~~	25	<b>+</b>				30			
166		Val	Glu	Glu	Mot	aat Aan	LLY	Dro	gya	aaa	Lgg	aaa	cca	aaa	atg	ata	ggg	144
167		Val	GIU	35	Met	ASII	Leu	PLO	40	ьys	Trp	гля	Pro		Met	тте	Gly	
168		ααa	att		aat	+++	2+0	222		200	~~~	+-+		45				100
169		GI w	Tla	Gl	99 L	Dho	Ile	Twa	yıa	aya	Cag	Lat	gag	caa	ata	gcc	gta	192
170		Gry	50	GIY	СТУ	FIIC	TTE	цу.s 55	vaı	AIG	GIII	TAL	61u	GIN	тте	Ата	vaı	
171		αaa		tat	ana	cat	aga		2+4	~~+	202	~+ ^						0.40
172		Glu	Yaa	Cve	994 61v	Wie	Arg	712	Mo+	79 L	mb-	y La	Tou	y La	gga Gl	200	aca	240
173		65	nuu	Cla	GTJ	птэ	70	ALG	Met	GTĀ	THI	75	Leu	val	GTĀ	PIO	80	
174			atc	aac	ata	att	gga	аσа	aat	cta	tta		a a a	2++	~~+	+ ~ ~		200
175		Pro	Val	Asn	Ile	Tle	Gly	Ara	Asn	T.e.ii	T.eu	Thr	Gln	Tlo	99 C	Cvc	Thr.	288
176						85	0-1	9	11011	Deu	90	1111	GIII	116	GLY	95	1111	
177		tta	aat	ttt	ccc		agt	cct	at.t.	αаа		αta	cca	ata	aaa		аал	336
178		Leu	Asn	Phe	Pro	Ile	Ser	Pro	Ile	Glu	Thr	Val	Pro	Val	Lve	Leu	L.ve	330
179					100					105				,	110	LCu	цуз	
180		cca	gga	atg	gat	qqc	cca	aaa	att		caa	t.aa	cca	t.t.a		αаа	αaa	384
181		Pro	Gly	Met	Asp	Gly	Pro	Lvs	Val	Lvs	Gln	Tro	Pro	Len	Thr	Glu	Glu	204
182			_	115	_	_		-	120	_				125			014	
183		aaa	ata	aaa	gca	tta	gta	qaa	atc	tat	aca	qaa	tta		aaσ	gaa	aaa	432
184		Lys	Ile	Lys	Ala	Leu	Val	Ğlu	Ile	Cys	Thr	Ğlu	Leu	Glu	Lvs	Glu	Glv	
185			130					135		-			140		-		1	
186		aaa	att	tca	aaa	att	ggg	cct	gaa	aat	cca	tac	aat	act	cca	qta	ttt	480
187		Lys	Ile	Ser	Lys	Ile	Gly	Pro	Glu	Asn	Pro	Tyr	Asn	Thr	Pro	Val	Phe	
188		145					150					155					160	
189		gcc	ata	aag	aaa	aag	aac	agt	act	aaa	tgg	aga	aaa	tta	gta	gat	ttc	528
190		Ala	Ile	Lys	Lys	Lys	Asn	Ser	Thr	Lys	Trp	Arg	Lys	Leu	Val	Āsp	Phe	
191						165					170	_	_			175		
192		aga	gaa	ctt	aat	aag	aga	act	caa	gac	ttc	tgg	gag	gtt	caa	tta	gga	576
193		Arg	Glu	Leu	Asn	Lys	Arg	Thr	Gln	Asp	Phe	Trp	Glu	Val	Gln	Leu	Gly	
194					180					185					190		_	
195	ı	ata	cca	cat	cca	gca	ggg	tta	aaa	aag	aat	aaa	tca	ata	aca	gta	ctg	624
196		Ile	Pro	His	Pro	Ala	Gly	Leu	Lys	Lys	Asn	Lys	Ser	Ile	Thr	Val	Leu	
197				195					200					205				
198	•	gat	gtg	ggt	gat	gca	tat	ttt	tca	gtt	ccc	tta	tgt	gaa	gac	ttc	agg	672





DATE: 12/13/2001 TIME: 20:27:05

Input Set : N:\Crf3\Refhold\I709905A.raw
Output Set: N:\CRF3\12132001\I709905A.raw

PATENT APPLICATION: US/09/709,905A

RAW SEQUENCE LISTING

								-		•								
199		Asp	Val	Gly	Asp	Ala	Tyr		Ser	Val	Pro	Leu	Cys	Glu	Asp	Phe	Arg	
200			210					215					220					
201		aag	tat	act	gca	ttt	acc	ata	cct	agt	gta	aac	aat	gag	act	cca	ggg	720
202		Lys	Tyr	Thr	Ата	Phe		IIe	Pro	Ser	Val		Asn	Glu	Thr	Pro	Gly	
203		225					230					235					240	
204		att	aga	tat	cag	tac	aat	gtg	ctt	cca	cag	gga	tgg	aaa	gga	ttc	acc	768
205		тте	Arg	туг	GIn		Asn	Val	Leu	Pro		Gly	Trp	Lys	Gly		Thr	
206 207		200	-+-	++-		245		_ 4			250					255		
208		cor	Tlo	Dho	Caa	Crra	age	atg	aca	aaa	atc	tta	gag	cct	ttt	aga	aaa	816
209		261	TIE	Pile	260	Cys	ser	Met	THE		тте	Leu	GIU	Pro		Arg	Lys	
210		caa	22+	002		2+2	~++	2+4	+-+	265	<b>.</b>				270			
211		Gln	aat Aen	Dro	Glu	Tla	yuu Wal	atc Ile	m	Cla	marr	atg	gat	gat	ttg	tat	gta	864
212		GIII	ASII	275	Giu	TTE	vai	TTE	280	GIII	TAT	met	ASP	285	ьeu	Tyr	vaı	
213		σσα	tct		tta	паа	ata	ggg		a+	242	~~~	222		~~~	~	-+-	010
214		Glv	Ser	Asn	T.All	Glu	Tlo	Gly	Cln	Udic	aya	31a	Trra	Tla	gay	yaa ci	CLG	912
215		011	290	5	шси	Olu	116	295	GIII	птэ	AIG	нта	300	TTE	GLU	GIU	ьeu	
216		aσa		tat	cta	taa	ааσ	tgg	ααa	+++	tac	202		M22	<b>~</b> ~ ~	222	aa+	060
217		Ara	Gln	Tvr	Len	Trn	Lvs	Trp	Glv	Dho	Cve	Thr	Dro	Glu	Cln	Two	Udc	960
218		305	<b></b>	-1-			310		O <sub>T</sub>	1 110	Cys	315	FIO	GIU	GIII	пуъ	320	
219			aaa	gaa	cct	cct		ctt	taa	atσ	aat		σаа	ctc	cat	ccc		1008
220		Gln	Lys	Glu	Pro	Pro	Phe	Leu	Trp	Met	Glv	Tvr	Glu	Len	Hig	Pro	guc Δen	1000
221			- 1 -			325					330	+1-	Olu	цси	1113	335	кэр	
222		aaa	tqq	aca	gta		cct	ata	ata	cta		gac	aaa	σa		333		1046
223		Lys	Trp	Thr	Val	Gln	Pro	Ile	Val	Leu	Pro	Asp	Lvs	<b>5</b> ~				1040
224		_	_		340					345			-1-					
226	<210>	SEQ	ID 1	10: 5	5													
227	<211>	LENG	STH:	1104	1													
228	<212>	TYPE	E: D1	ΙA														
229	<213>	ORGA	NISN	1: Hu	ıman	Immu	inode	efici	lency	, Vii	cus (	(HIV)						
	<220>																	
	<221>																	
	<222>																	
	<223>					ON: I	IIV I	rote	ease									
	<221>																	
	<222>																	
236	<223>	OTHE	CR IN	IFORM	IATIC	N: E	orti	on c	of HI	V Re	evers	se Tr	ansc	ript	ase			
	<400>	-																
238		CCT	cag	atc	act	ctt	tgg	caa	cga	ccc	atc	gtc	aca	ata	aag	rta	ggg	48
239			GIN	тте	Thr		Trp	Gln	Arg	Pro		Val	Thr	Ile	Lys		Gly	
240 241		1		-+-		5					10					15		
241		999	Cla	CLa	agg	gaa	gct	cta	tta	gat	aca	gga	gca	gat	gat	aca	ata	96
243		GIY	GIII	ьеu		GIU	Ата	Leu	Leu		Thr	GIĀ	Ата	Asp		Thr	He	
243		ata	กลล	αaα	20 ata	act	++~	003	~~~	25	+~~	200	995		30	- <del>-</del> -		1 4 4
245		Tla	Glu	yac Aen	Tla	act Th∽	LLY	cca	gya Cl	aya Are	Lgg	aca mb	CCa Dwa	aaa	atg	ata	ggg	144
246		11C	Jiu	35	TTC	TIIT	neu	Pro	40	мтд	ттр	THE	LT.O		met	тте	стА	
247		ασα	att		aa+	+++	ato	aaa		ana	cac	tat	πa+	45	a+ a	000	2+2	100
248		Gl∨	Ile	Glv	Glv	Phe	Val	Lys	y cu Val	Ara	Gln	Tur	yat Den	cay cln	Tla	Dro	ald Tlo	192
		1		1	1			~, 5	, u _	9	<b>9</b> ±11	- Y -	wab	G111	116	ب الاست. مائلاسية	the Sel	nuence Listin

Use of n and/or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.





## VERIFICATION SUMMARY

L:8 M:270 C: Current Application Number differs, Wrong Format

PATENT APPLICATION: US/09/709,905A

DATE: 12/13/2001 TIME: 20:27:06

Input Set : N:\Crf3\Refhold\I709905A.raw
Output Set: N:\CRF3\12132001\I709905A.raw

```
L:41 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:65 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:81 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:84 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:129 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:172 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:239 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:251 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:263 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:411 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L\!:\!412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:418 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:491 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:494 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:576 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:630 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:636 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:664 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:667 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:706 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:712 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:749\ M:341\ W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:764 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:800 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
\tt L\!:\!885~M\!:\!341~W\!: (46) "n" or "Xaa" used, for SEQ ID#:12
L\!:\!916 M\!:\!341 W\!: (46) "n" or "Xaa" used, for SEQ ID#:13
L\!:\!919 M\!:\!341 W\!: (46) "n" or "Xaa" used, for SEQ ID#:13
L:952\ M:341\ W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:967 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:1049 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:1058 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:1092 \ M:341 \ W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:1095 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L\!:\!1134 M\!:\!341 W\!: (46) "n" or "Xaa" used, for SEQ ID#:15
L\!:\!1146 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L\!:\!1152 M\!:\!341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:1195 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:1225 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:1256 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:1265 \ M:341 \ W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:1298 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:1301 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:1313 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:1316 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/709,905A

DATE: 12/13/2001 TIME: 20:27:06

Input Set : N:\Crf3\Refhold\I709905A.raw Output Set: N:\CRF3\12132001\I709905A.raw

 $L\!:\!1324$   $M\!:\!341$   $W\!:$  (46) "n" or "Xaa" used, for SEQ ID#:17 L:1350 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18  $L\!:\!1377\ M\!:\!341\ W\!:$  (46) "n" or "Xaa" used, for SEQ ID#:18

L:2102 M:351 W: Sequence data Name/Key Feature Out-of-Range, SEQ ID#:27, CDS LOCATION:

(298)...(1116)